Tetraphase Pharmaceuticals, Inc. Securities Litigation
On or around 04/09/2020 (Date of last review)
Filing Date: April 09, 2020
According to the Complaint, Tetraphase Pharmaceuticals, Inc. is a biopharmaceutical company that uses its proprietary chemistry technology to create novel tetracyclines for serious and life-threatening conditions, including infections caused by many of the multidrug-resistant bacteria highlighted as urgent public health threats by the World Health Organization and the Centers for Disease Control and Prevention.
This action stems from a proposed transaction announced on March 16, 2020, pursuant to which Tetraphase Pharmaceuticals, Inc. will be acquired by AcelRx Pharmaceuticals, Inc.
On March 15, 2020, Tetraphase’s Board of Directors caused the Company to enter into an agreement and plan of merger with AcelRx. Pursuant to the terms of the Merger Agreement, Tetraphase’s stockholders will receive 0.6303 shares of Parent common stock and one contingent right value (“CVR”) for each share of Tetraphase common stock they own.
Company & Securities Information
Defendant: Tetraphase Pharmaceuticals, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: TTPH
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Patrick Plumley, et al. v. Tetraphase Pharmaceuticals, Inc., et al.
COURT: D. Delaware
DOCKET #: 20-CV-00496
JUDGE: Hon. Maryellen Noreika
DATE FILED: 04/09/2020
CLASS PERIOD START: 03/16/2020
CLASS PERIOD END: 04/09/2020
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Rigrodsky & Long, P.A. (Wilmington)
RM Law, P.C. (Berwyn)
First Identified Complaint (FIC) Filings:
Complaint for Violation of the Securities Exchange Act of 1934
U.S. District Court Civil Docket
—Reference Complaint Complaint Related Data is not available
Related District Court Filings
—Related District Court Filings Data is not available